Drugs that contain Vosoritide
1. Voxzogo patents expiration
VOXZOGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
VOXZOGO family patents
